معرفی
Chandrabali Bhattacharya serves as Assistant Professor in the Department of Chemistry and Biochemistry at the University of Nevada, Las Vegas, where she founded and directs the mRNA Nanomedicine Program to advance mRNA therapeutics research in Nevada. Her work pioneers targeted delivery systems for mRNA using carbohydrate-protein interaction principles.
Dr. Bhattacharya earned bachelor's and master's degrees in chemistry from Presidency College Kolkata and Indian Institute of Technology Kharagpur. She completed her Ph.D. in bioorganic chemistry at Arizona State University under Dr. Sidney M. Hecht, investigating bleomycin's disaccharide moiety in tumor targeting. Subsequent postdoctoral training included glycosaminoglycan research with Dr. Linda Hsieh-Wilson at Caltech and mRNA delivery development with Drs. Daniel Anderson and Robert Langer at MIT's Koch Institute as a Juvenile Diabetes Research Foundation Fellow.
Her research integrates organic chemistry, glycobiology, and nanomedicine to design precision mRNA delivery vehicles. The Bhattacharya Lab specializes in glycolipid-based nanoparticles that target immune cells for cancer immunotherapy, including CAR-T cell engineering and personalized neoantigen vaccines. By leveraging disease-specific glycation patterns, her team develops 'living drugs' through reprogrammed T cells and dendritic cell-targeted vaccines.
Analysis of her 2024-2025 publications reveals groundbreaking work in expanding mRNA delivery beyond liver/lung targets. Key innovations include Cortico LNPs for spleen-selective delivery (enabling autoimmune disease treatments) and ENDO LNPs for pancreatic targeting (with implications for diabetes and pancreatic cancer therapies). Her research consistently bridges fundamental glycochemistry with clinical translation in oncology and immunology.
Her scientific recognition includes:
- Juvenile Diabetes Research Foundation Fellowship
Supported by competitive research funding, Dr. Bhattacharya leads a multidisciplinary team developing next-generation delivery platforms. Her mRNA Nanomedicine Program fosters statewide collaboration to position Nevada as a hub for RNA therapeutics innovation, with current projects focused on overcoming tissue-specific delivery barriers for cancer and metabolic diseases.
The Bhattacharya Lab operates at the chemistry-biology-engineering interface, combining synthetic organic chemistry with cellular immunology to solve delivery challenges. Future work will expand organ-targeting capabilities and accelerate clinical translation of mRNA-based cancer immunotherapies through industry partnerships and novel biomaterial design.
